Investors

Press Releases

Press Releases

February 1, 2022
– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related

Data Provided by Refinitiv. Minimum 15 minutes delayed.